FrancophonIA/ELRC3.0 huggingface dataset:
English: In the postmarketing setting, the risk of PML has been well characterized over the first 6 years of treatment with the identification of different levels of PML risk in different patient subgroups.
Croatian: Nakon puštanja lijeka u promet rizik od PML-a dobro je karakteriziran prvih 6 godina liječenja te su prepoznate različite razine rizika od PML-a u različitim podgrupama bolesnika.
English: • Present data from PK/PD/efficacy modelling from clinical trial data that suggests efficacy of 6 week dosing more similar to 4 weeks if occurs >1 year of 4 weekly treatment
Croatian: • Predstavite podatke iz modeliranja PK-a/PD-a/djelotvornosti iz podataka kliničkih ispitivanja koji sugeriraju da je djelotvornost doziranja od 6 tjedana sličnija onom od 4 tjedna ako do njega dođe > 1 godinu liječenja u intervalima od 4 tjedna
English: Some cases have occurred in patients with central nervous system (CNS) herpes infections (e.g. herpes meningitis and encephalitis).
Croatian: Neki slučajevi zabilježeni su u bolesnika s herpes infekcijama središnjeg živčanog sustava (SŽS) (npr. herpesnim meningitisom i encefalitisom).
English: - Changes in personality and behaviour such as confusion, delirium or loss of consciousness, seizures (fits), headache, nausea / vomiting, stiff neck, extreme sensitivity to bright light, fever, rash (anywhere on the body).
Croatian: − promjene u osobnosti i ponašanju, kao što su: smetenost, delirij ili gubitak svijesti, epileptičke napadaje, glavobolju, mučninu / povraćanje, ukočenost vrata, izrazitu osjetljivost na jako svjetlo, vrućicu, osip (bilo gdje na tijelu).
English: MRI evaluations for T1-weighted gadolinium (Gd)-enhancing lesions and T2-hyperintense lesions were performed annually.
Croatian: Magnetske rezonancije za lezije T1 utvrđene gadolinijem (Gd) i za hiperintenzivne lezije T2 napravljene su jedanput godišnje.
English: • The need to inform the National Competent Authority about any cases of PML
Croatian: • Nacionalno regulatorno tijelo treba obavijestiti o svakom slučaju PML-a
English: Within this analysis, a limited subset of patients with data available prior to treatment (158 of the 621 patients) demonstrated a reduction in ARR from 1.466 (95% CI 1.337, 1.604) prior to treatment to 0.110 (95% CI 0.094, 0.128).
Croatian: U toj analizi, ograničena podskupina bolesnika s podacima dostupnim prije liječenja (158 od 621 bolesnika) pokazala je smanjenje godišnje stope relapsa od 1,466 (95% CI 1,337; 1,604) prije liječenja do 0,110 (95% CI 0,094; 0,128).
English: In a few patients who use TYSABRI, over time the body's natural defence may stop TYSABRI from working properly (the body develops antibodies to TYSABRI).
Croatian: U nekoliko bolesnika koji primaju TYSABRI prirodni tjelesni obrambeni mehanizam može s vremenom zaustaviti djelovanje TYSABRIJA (tijelo stvara protutijela na TYSABRI).
English: IRIS is generally suspected when patients with PML exhibit signs of clinical worsening usually, but not always, accompanied by gadolinium enhancement of PML lesions with or without mass effect on brain MRI.
Croatian: Na IRIS se općenito sumnja kada bolesnik s PML-om pokazuje znakove kliničkog pogoršanja obično, ali ne i uvijek popraćene gadolinijskim povećanjem lezija PML-a s efektom mase na MR-u mozga ili bez njega.
English: Use of TYSABRI has been associated with an increased risk of PML, an opportunistic infection caused by JC virus, which may be fatal or result in severe disability.
Croatian: Primjena TYSABRIJA povezana je s povećanim rizikom od PML-a, oportunističke infekcije uzrokovane JC virusom, koja može biti smrtonosna ili može biti uzrokom teškog invaliditeta.
English: PML should be considered as a differential diagnosis in any MS patient taking TYSABRI presenting with neurological symptoms and/or new brain lesions in MRI.
Croatian: PML treba razmotriti kao diferencijalnu dijagnozu u svakog bolesnika s MS-om koji prima TYSABRI i prezentira neurološke simptomime i/ili nove moždane lezije na MR-u.
English: Serious cases of ARN, either affecting one or both eyes, led to blindness in some patients.
Croatian: Ozbiljni slučajevi akutne retinalne nekroze koji su zahvatili jedno ili oba oka doveli su do sljepoće u nekih bolesnika.
English: No studies have been performed to evaluate the efficacy and safety of TYSABRI when switching patients from DMTs with an immunosuppressant effect.
Croatian: Nisu provedena ispitivanja kako bi se procijenile djelotvornost i sigurnost lijeka TYSABRI kada bolesnici prelaze s terapija koje mijenjaju tijek bolesti i imaju imunosupresivni učinak.
English: • Treatment initiation and treatment continuation forms
Croatian: • Obrasce za početak i nastavak liječenja
English: Suspension of TYSABRI therapy, for short duration (days or weeks), is not expected to compromise therapeutic efficacy based on the pharmacodynamics of the drug.
Croatian: Ne očekuje se da bi kratka obustava terapije lijekom TYSABRI (nekoliko dana ili tjedana) mogla ugroziti terapijsku djelotvornost na temelju farmakodinamike lijeka.
English: • Any unused medicinal product or waste material must be disposed of in accordance with local requirements.
Croatian: • Neiskorišteni lijek ili otpadni materijal potrebno je zbrinuti sukladno nacionalnim propisima.
English: Short courses of corticosteroids can be used in combination with TYSABRI.
Croatian: Kratkotrajna primjena kortikosteroida stoga se može primjenjivati u kombinaciji s TYSABRIJEM.
English: Current pharmacokinetic/pharmacodynamic statistical modelling and simulation indicate that the risk of MS disease activity for patients switching to longer dosing intervals may be higher for patients with body weight >80kg or those with dosing intervals ≥7 weeks.
Croatian: Trenutačni farmakokinetički/farmakodinamički statistički modeli i simulacije upućuju na to da bi rizik od aktivnosti multiple skleroze u bolesnika koji prijeđu na dulji interval doziranja mogao biti veći u bolesnika tjelesne težine > 80 kg ili onih čiji je interval doziranja ≥ 7 tjedana.
English: Disruption of these molecular interactions prevents transmigration of mononuclear leukocytes across the endothelium into inflamed parenchymal tissue.
Croatian: Prekid ovih molekulskih interakcija sprečava prijelaz mononuklearnih leukocita preko endotela u upaljeno tkivo parenhima.
English: A post-marketing meta-analysis was conducted using data from 621 paediatric MS patients treated with TYSABRI (median age 17 years, range was 7-18 years, 91% aged ≥14 years).
Croatian: Provedena je metaanaliza na podacima nakon stavljanja lijeka u promet za 621 pedijatrijskog bolesnika s multiplom sklerozom liječenog TYSABRIJEM (medijan dobi 17 godina, raspon dobi 7-18 godina, 91% u dobi ≥14 godina).
English: • Details of the patient, treating doctor and date Tysabri was started
Croatian: • Pojedinosti o bolesniku, liječniku i datumu početka uzimanja lijeka Tysabri
English: Natalizumab blocks the interaction of α4β7 integrin with the mucosal addressin cell adhesion molecule-1 (MadCAM-1).
Croatian: Natalizumab sprečava interakciju integrina α4β7 s adhezijskim molekulama-1 MadCAM-1 (engl. mucosal addressin cell adhesion molecule-1).
English: When switching patients from another DMT to TYSABRI, the half-life and mode of action of the other therapy must be considered in order to avoid an additive immune effect whilst at the same time minimising the risk of disease reactivation.
Croatian: Kada bolesnici prelaze s druge terapije koja mijenja tijek bolesti na TYSABRI, mora se uzeti u obzir poluvijek i način djelovanja te druge terapije kako bi se izbjegao aditivni imunološki učinak, a da se istodobno minimizira rizik od reaktivacije bolesti.
English: Clinical neurologic deterioration in patients with PML and/or JCV GCN may be caused by JCVmediated destruction of CNS tissue, or upon restoration of immune function, by an intracerebral immune inflammatory reaction known as immune reconstitution inflammatory syndrome (IRIS).
Croatian: Kliničko neurološko pogoršanje u bolesnika s PML-om i/ili JCV GCN-om može biti izazvano uništenjem tkiva SŽS-a posredovanim JCV-om ili, nakon vraćanja funkcije imunosnog sustava, intracerebralnom imunosnom upalnom reakcijom poznatom pod nazivom imunorekonstitucijski upalni sindrom (IRIS).
English: In post-marketing experience, there have been reports of hypersensitivity reactions which have occurred with one or more of the following associated symptoms: hypotension, hypertension, chest pain, chest discomfort, dyspnoea, angioedema, in addition to more usual symptoms such as rash and urticaria.
Croatian: Nakon stavljanja lijeka u promet prijavljene su reakcije preosjetljivosti povezane s jednim ili više slijedećih simptoma: hipotenzija, hipertenzija, bol u prsištu, nelagoda u prsištu, dispneja, angioedem kao dodatnim simptomima uz uobičajene, kao što su osip i urtikarija.
English: • If your doctor has told you that you have PML (progressive multifocal leukoencephalopathy).
Croatian: • ako Vam je liječnik rekao da imate progresivnu multifokalnu leukoencefalopatiju (PML).
English: • Present the results of the TOUCH analysis which showed clinically and statistically significant reduction in PML risk in patients who are treated with EID (dosing interval 6 weeks) compared to Standard interval dosing (dosing interval 4 weeks).
Croatian: • Predstavite rezultate analize TOUCH koji su pokazali klinički i statistički značajno smanjenje rizika od PML-a u bolesnika liječenih EID-om (interval doziranja od 6 tjedana) u usporedbi sa standardnim intervalom doziranja (interval doziranja od 4 tjedna).
English: Discussion of PML in TYSABRI Treated Patients
Croatian: Rasprava o PML-u u bolesnika liječenih lijekom TYSABRI
English: Your doctor may test your blood to check if you have antibodies to the JC virus before you start treatment with TYSABRI.
Croatian: Liječnik može obaviti analizu krvi kako bi provjerio imate li protutijela na JC virus prije nego što počne liječenje TYSABRIJEM.
English: These medicines cannot be used with TYSABRI (see Using other medicines, below).
Croatian: Ti se lijekovi ne smiju primjenjivati s TYSABRIJEM (pogledajte niže: Drugi lijekovi i TYSABRI).
English: You will also find this information in the Patient Alert Card you have been given by your doctor.
Croatian: Ove informacije naći ćete također u Kartici s upozorenjima za bolesnika koju ste dobili od svog liječnika.
English: 2) Intravenous methylprednisolone (1 g/d for 3 or 5 d) with oral taper over 2 months
Croatian: 2) Intravenski metilprednizolon (1 g/dan tijekom 3 ili 5 dana) s oralnim postupnim smanjenjem tijekom 2 mjeseca
English: Efficacy has been modelled for patients who switch to longer dosing after ≥1 year of approved TYSABRI dosing and who did not experience a relapse in the year prior to switching.
Croatian: Djelotvornost je prilagođena bolesnicima koji prijeđu na dulje doziranje nakon ≥1 godinu odobrenog doziranja TYSABRIJA i u kojih u godinu dana prije prelaska nije došlo do relapsa.
English: Within 3 months prior to starting TYSABRI Annually during treatment with TYSABRI More frequent MRIs (e.g. on a 3 to 6 monthly basis) for patients at high risk for PML.
Croatian: Unutar 3 mjeseca prije početka primanja TYSABRIJA Svake godine tijekom liječenja TYSABRIJEM Češća snimanja MR-om (npr. svakih 3 do 6 mjeseci) za bolesnike s većim rizikom od PML-a.
English: Your doctor should do a blood test in order to test for abnormalities and whether you have antibodies to the JC virus.
Croatian: Liječnik Vam mora napraviti pretragu krvi kako bi se provjerilo postoje li abnormalnosti i imate li protutijela na virus JC.
English: Serious adverse events were evaluated in 621 MS paediatric patients included in a meta-analysis (see also Section 5.1).
Croatian: Ozbiljne nuspojave procijenjene su u 621 pedijatrijskog bolesnika s multiplom sklerozom uključenog u metaanalizu (vidjeti također dio 5.1).
English: Patients should not be tested for anti-JCV antibodies within 2 weeks of PLEX due to removal of antibodies from the serum, or within 6 months of IVIg (i.e. 6 months = 5x half-life for immunoglobulins).
Croatian: Bolesnike se ne smije testirati na anti-JCV protutijela unutar 2 tjedna od provedbe plazmafereze zbog uklanjanja protutijela iz seruma ili unutar 6 mjeseci od primjene i.v.Ig (tj. 6 mjeseci = 5 x poluvijek imunoglobulina).
English: Prior treatment with immunosuppressive or immunomodulatory therapies
Croatian: Prethodno liječenje imunosupresivnim ili imunomodulacijskim terapijama
English: • Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.
Croatian: ili • Bolesnici s teškom brzonapredujućom relapsno-remitentnom multiplom sklerozom definiranom s 2 ili više onesposobljavajućih relapsa u jednoj godini i s 1 ili više lezija utvrđenih gadolinijem na magnetskoj rezonanciji mozga ili sa značajnim povećanjem opterećenja T2 lezijama u odnosu na prethodnu magnetsku rezonanciju.
English: • Present data from PK/PD/efficacy modelling from the RESTORE study which indicates that risk of return of MS disease activity more likely with increased body weight (>80kg) or longer dosing intervals (>7 weeks).
Croatian: • Predstavite podatke iz modeliranja PK-a/PD-a/djelotvornosti iz ispitivanja RESTORE koji upućuju na to da je rizik od povratka aktivnosti bolesti MS-a vjerojatniji uz veću tjelesnu težinu (> 80 kg) ili dulje intervale doziranja (>7 tjedana).
English: • You will also find this information in the Patient Alert Card you have been given by your doctor.
Croatian: • Te informacije ćete također naći u Kartici s upozorenjima za bolesnika koju ste dobili od svog liječnika.
English: Patients can switch directly from beta interferon or glatiramer acetate to TYSABRI providing there are no signs of relevant treatment-related abnormalities e.g. neutropenia and, lymphopenia.
Croatian: Bolesnici mogu izravno prijeći s interferona beta ili glatiramer acetata na TYSABRI, uz uvjet da nema znakova značajnih abnormalnosti povezanih s liječenjem, poput neutropenije i limfopenije.
English: This reduces nerve damage caused by MS.
Croatian: Tako smanjuje oštećenje živaca koje uzrokuje multipla skleroza.
English: In addition to this leaflet you will be given a Patient Alert Card, which contains important safety information that you need to know before you are given TYSABRI (pronounced tie-SA-bree) and during treatment with TYSABRI.
Croatian: Osim ove upute dobit ćete i Karticu s upozorenjima za bolesnika koja sadrži važne sigurnosne informacije u koje morate biti upućeni prije nego što Vam je dan TYSABRI i tijekom liječenja
English: TYSABRI is a clear, colourless to slightly cloudy liquid.
Croatian: TYSABRI je bistra, bezbojna do blago zamućena tekućina.
English: The presence of persistent antinatalizumab antibodies increased natalizumab clearance approximately 3-fold, consistent with reduced serum natalizumab concentrations observed in persistently antibody-positive patients, (see section 4.8).
Croatian: Prisustvo perzistirajućih anti-natalizumab protutijela povećalo je klirens natalizumaba oko 3 puta, što je u skladu sa smanjenim koncentracijama natalizumaba u serumu primijećenim u bolesnika koji pokazuju trajno prisustvo protutijela (vidjeti dio 4.8).
English: In patients treated with TYSABRI, IRIS has occurred within days to several weeks after TYSABRI removal by plasma exchange (PLEX) or immunoabsorption (IA).
Croatian: U bolesnika liječenih lijekom TYSABRI do IRIS-a je došlo u roku od nekoliko dana do nekoliko tjedana nakon što je TYSABRI uklonjen izmjenom plazme (PLEX-om) ili imunoapsorpcijom (IA-om).
English: An accelerated elimination procedure as defined in the teriflunomide Summary of Product Characteristics is recommended or alternatively washout period should not be shorter than 3.5 months.
Croatian: Preporučuje se ubrzani postupak eliminacije opisan u sažetku opisa svojstava lijeka za teriflunomid ili, u drugom slučaju, razdoblje ispiranja lijeka iz organizma ne smije biti kraće od 3,5 mjeseca.
English: Do not use TYSABRI
Croatian: Nemojte primati TYSABRI
English: 15 ml concentrate in a vial (type I glass) with a stopper (chlorobutyl rubber) and a seal (aluminium) with a flip-off cap.
Croatian: 15 ml koncentrata u bočici (staklo tipa I) s čepom (od klorobutilne gume) i zatvaračem (od aluminija)
English: The clinical worsening is a result of local inflammatory reaction, including oedema, and manifests as a worsening of neurological symptoms including hemiparesis, ataxia, speech abnormalities, visual disturbance, cognitive/behavioural changes and seizure (dependent on the site of IRIS).
Croatian: Kliničko pogoršanje posljedica je lokalne upalne reakcije, uključujući edem, a manifestira se pogoršanjem neuroloških simptoma, uključujući hemiparezu, ataksiju, poremećaje govora, smetnje vida, kognitivne/bihevioralne promjene i
English: The symptoms of MS vary from patient to patient, and you may experience some or none of them.
Croatian: Simptomi multiple skleroze razlikuju se od bolesnika do bolesnika, a u Vas se mogu javiti neki od simptoma ili niti jedan.
English: The efficacy of TYSABRI when administered with EID has not been established, and therefore the benefit/risk balance of EID is unknown (see section 4.4).
Croatian: Djelotvornost TYSABRIJA primijenjenog prema EID-u nije utvrđena, pa je omjer koristi i rizika EID-a nepoznat (vidjeti dio 4.4).
English: All physicians who intend to prescribe TYSABRI must ensure they are familiar with the Physician Information and Management Guidelines.
Croatian: Svi kliničari koji namjeravaju propisati TYSABRI, moraju dobro poznavati Informaciju za liječnike i
English: In Phase 3 MS clinical trials, concomitant treatment of relapses with a short course of corticosteroids was not associated with an increased rate of infection.
Croatian: U kliničkim ispitivanjima faze 3 multiple skleroze, istovremeno liječenje relapsa kratkom terapijom kortikosteroidima i TYSABRIJEM nije bilo povezano s povećanom stopom infekcija.
English: • The diluted medicinal product is to be used as soon as possible and within 8 hours of dilution.
Croatian: • Razrijeđeni lijek trebate upotrijebiti što prije i unutar 8 sati nakon razrjeđivanja.
English: Currently available evidence suggests that the risk of PML is low at an index equal to or below 0.9 and increases substantially above 1.5 for patients who have been on treatment with TYSABRI for longer than 2 years.
Croatian: Trenutačno dostupni dokazi upućuju na to da je rizik od PML-a nizak pri indeksu jednakom 0,9 ili nižem, a znatno se povećava iznad 1,5 za bolesnike koji su liječeni lijekom TYSABRI dulje od 2 godine.
English: • Use aseptic technique when preparing TYSABRI solution for intravenous (IV) infusion.
Croatian: • Koristite aseptičku tehniku za pripremu otopine TYSABRIJA za intravensku (i.v.) infuziju.
English: The interim analysis showed a lower risk of PML in patients treated with EID (hazard ratio = 0.06 95% CI of hazard ratio = 0.01- 0.22).
Croatian: Interim analiza pokazala je manji rizik od PML-a u bolesnika liječenih prema EID-u (omjer hazarda = 0,06; 95% CI omjera hazarda = 0,01 - 0,22).
English: Patients who have experienced a hypersensitivity reaction must be permanently discontinued from treatment with TYSABRI.
Croatian: Bolesnici kod kojih se pojavi reakcija preosjetljivosti moraju trajno prekinuti liječenje TYSABRIJEM.
English: Before you start treatment with TYSABRI, it is important that you and your doctor have discussed the benefits you would expect to receive from this treatment and the risks that are associated with it.
Croatian: Što morate znati prije nego počnete primati TYSABRI Prije nego što započnete liječenje TYSABRIJEM važno je da s liječnikom razmotrite koristi koje očekujete od ovog liječenja i rizik povezan s tim.
English: o That the risk of PML increases with increasing duration of treatment and that treatment beyond 24 months carries additional risk and other factors associated with an increased risk for the development of PML
Croatian: o Da rizik za PML raste s produljenjem trajanja liječenja te da liječenje u trajanju duljem od 24 mjeseca nosi dodatni rizik i ostale čimbenike povezane s povećanim rizikom za
English: Diluted solution:
Croatian: Razrijeđena otopina:
English: Acute retinal necrosis (ARN) is a rare fulminant viral infection of the retina caused by the family of herpes viruses (e.g. varicella zoster).
Croatian: Akutna retinalna nekroza rijetka je fulminantna virusna infekcija mrežnice koju uzrokuje obitelj herpes virusa (npr. varicella zoster).
English: Keep the leaflet and Alert Card with you during treatment and for six months after the last dose of TYSABRI, since side effects may occur even after you have stopped treatment.
Croatian: Nosite uz sebe ovu uputu i Karticu s upozorenjima za bolesnika tijekom liječenja te još šest mjeseci nakon zadnje doze TYSABRIJA, budući da se nuspojave mogu javiti i nakon što ste prekinuli liječenje.
English: To switch from some MS medicines, your doctor may advise you to wait for a certain time to ensure that most of the previous medicine has left your body.
Croatian: Kod prijelaza na TYSABRI s nekog drugog lijeka protiv multiple skleroze liječnik će Vam možda savjetovati da pričekate neko vrijeme kako bi se osiguralo da je prethodni lijek većinom uklonjen iz tijela.
English: TYSABRI is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups:
Croatian: TYSABRI je indiciran kao imunomodulacijska monoterapija za visoko aktivnu relapsno-remitentnu multiplu sklerozu u sljedećih skupina odraslih bolesnika:
English: In order to improve traceability of biological medicinal products, the product name (Tysabri) and batch number of the administered product should be clearly recorded.
Croatian: Kako bi se poboljšala sljedivost bioloških lijekova, naziv (Tysabri) i broj serije primijenjenog lijeka potrebno je jasno evidentirati.
English: o If treatment is to be continued for longer than 24 months, the need to inform patients about the increased risk of PML and provide them with a copy of the treatment continuation form o Description of Immune Reconstitution Inflammatory Syndrome (IRIS) is provided
Croatian: Ako se liječenje nastavlja dulje od 24 mjeseca, potreba za informiranjem bolesnika o povećanom riziku od PML-a i davanje primjerka obrasca za prekid liječenja o Osiguran je opis imunorekonstitucijskog upalnog sindroma (IRIS-a)
English: Hazard ratio for disability progression was 0.36 (95% CI: 0.17, 0.76) p = 0.008.
Croatian: Omjer hazarda od progresije onesposobljenosti bio je 0,36 (95% CI : 0,17, 0,76) p = 0,008.
English: • Information on PML and IRIS including the risk of developing PML during TYSABRI
Croatian: • Informacije o PML-u i IRIS-u, uključujući rizik od pojave PML-a tijekom liječenja
English: Specifically, natalizumab binds to the α4β1 integrin, blocking the interaction with its cognate receptor, vascular cell adhesion molecule-1 (VCAM-1), and ligands osteopontin, and an alternatively spliced domain of fibronectin, connecting segment-1 (CS-1).
Croatian: Natalizumab se specifično veže za integrin α4β1 te time sprečava njegovu interakciju s receptorom, vaskularnom staničnom adhezijskom molekulom-1 (VCAM-1) i ligandima osteopontinom i veznim segmentom-1 (engl. connecting segment-1, CS-1) koji predstavlja alternativno izrezanu domenu fibronektina.
English: If you miss your dose of TYSABRI
Croatian: Ako ste propustili dozu TYSABRIJA
English: In such cases where TYSABRI therapy was discontinued the elevated eosinophil levels resolved.
Croatian: U takvim slučajevima kada je terapija TYSABRIJEM prekinuta povišene razine eozinofila vratile su se na normalne vrijednosti.
English: TYSABRI is used to treat multiple sclerosis (MS).
Croatian: TYSABRI se primjenjuje za liječenje multiple skleroze.
English: • That the aim of the treatment initiation form is to provide patients with information on PML
Croatian: • Da je svrha obrasca za početak liječenja pružiti bolesniku informacije o PML i IRIS-u
English: 1) Oral prednisone 1.5 mg/kg/d x 2 wks with taper over 2 months
Croatian: 1) Prednizon peroralnim putem u dozi od 1,5 mg/kg/dan x 2 tjedna s postupnim smanjenjem tijekom 2 mjeseca